Bicara Therapeutics Inc. (NASDAQ: BCAX) announced plans for an underwritten public offering of $150 million in common stock, with underwriters holding a 30-day option to purchase an additional $22.5 million in shares. The clinical-stage biopharmaceutical company intends to deploy the capital across multiple strategic initiatives to accelerate its clinical and commercial operations.
The company plans to allocate proceeds primarily toward advancing its lead therapeutic candidate, ficerafusp alfa, through ongoing clinical development programs. Additional funds will support the establishment of commercial infrastructure and operations required for potential market entry, including manufacturing scale-up and sales force development.
Bicara will also utilize portions of the offering to fund regulatory submissions and approval processes necessary for commercial launch activities. The capital raise represents a significant milestone for the clinical-stage company as it progresses toward potential commercialization of its pipeline assets.